Introduction
============

Long-term cigarette smoking induces many pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory disorders in the elderly population [@B1]. Given the tremendous impact of COPD on death and chronic disability, the prevention of COPD is particularly important. COPD is thought to involve chronic inflammation not only in the respiratory system, but also in the rest of the body resulting from the spread of inflammatory mediators from the lungs [@B2].

Metabolic syndrome is a predominant comorbidity of COPD [@B3]-[@B7]. Adipocytokines, including adiponectin, play a significant role in the pathogenesis of metabolic syndrome [@B8], and were noted as factors contributing to COPD. Tomoda et al. demonstrated an increase in plasma adiponectin levels in underweight COPD patients [@B9]. Recently, it was demonstrated that higher adiponectin levels were associated with a higher risk of all-cause mortality in COPD patients [@B10]. In addition, the Lung Health Study analysis demonstrated that adiponectin is a complex biomarker in COPD that is associated with a decreased risk of cardiovascular events, but an increased risk of respiratory mortality [@B11]. These results suggest that adiponectin plays a proinflammatory or pulmonary-destructive role in the pathogenesis of COPD.

However, studies using adiponectin gene-targeted mice have yielded controversial results. Two studies reported that adiponectin-null mice developed a COPD-like phenotype [@B12], [@B13]. In contrast, others have demonstrated that adiponectin knockout mice were protected from the development of emphysema induced by long-term exposure to cigarette smoke [@B14]. These contrasting results from animal studies complicate the interpretation of the role of adiponectin. Thus, whether adiponectin plays a pulmonary-protective or pulmonary-destructive role in the pathogenesis of COPD remains unclear.

To date, the relationship between plasma adiponectin levels and pulmonary function has not been demonstrated in a general population. This study aimed to investigate this relationship in order to determine the role of adiponectin in the lungs.

Methods
=======

Study population
----------------

This study formed part of the Molecular Epidemiological Study of the Regional Characteristics of the 21^st^ Century Centers of Excellence (COE) Program and the Global Centers of Excellence Program in Japan [@B3], [@B15]-[@B22]. The study was approved by the Ethics Committee of Yamagata University School of Medicine, and all participants provided their written informed consent.

The study used data from an annual community health check-up in which all residents of Takahata, a town in northern Japan, aged 40 years or older were invited to participate. From 2004 to 2006, 1,579 men and 1,941 women (total, 3,520 subjects) enrolled in the study and underwent initial spirometric examinations. We excluded 267 subjects from the analysis because their spirometry data did not meet the specified criteria. The data from 3,253 subjects (1,500 men and 1,753 women) were utilized in the final statistical analysis. The subjects\' medical histories, smoking habits, current use of medications, and clinical symptoms were documented using a self-reported questionnaire. The lifetime consumption of cigarettes was expressed as the Brinkman index (BI: number of cigarettes per day × years of smoking) [@B3], [@B19]. In 2011, spirometry was re-performed on 873 subjects. After the exclusion of 1 subject resulting from an error in spirometry measurements, the data from 872 subjects (405 men and 467 women) were used for a longitudinal analysis.

Measurements
------------

Fasting blood samples were taken from the antecubital vein of the subjects, and immediately transferred to chilled tubes. Plasma adiponectin levels were measured by using an enzyme immunoassay (Otsuka Pharmaceutical Co., Tokyo, Japan) [@B23].

Spirometric parameters (FVC and FEV~1~) were measured using standard techniques, with subjects performing FVC maneuvers on a CHESTAC-25 part II EX instrument (Chest Corp., Tokyo, Japan) according to the guidelines of the Japanese Respiratory Society (JRS) [@B24]. A bronchodilator was not administered prior to spirometry. The highest value of at least 3 FVC maneuvers by each subject was used for the analysis. The results were assessed by 2 pulmonary physicians, who visually inspected the flow-volume curves and excluded subjects with inadequate data as defined by the JRS criteria [@B24]. Subjects\' pulmonary functions were classified as follows: normal, %FVC ≥ 80 and FEV~1~/FVC ≥ 0.7; restrictive, %FVC \< 80 and FEV~1~/FVC ≥ 0.7; obstructive, %FVC ≥ 80 and FEV~1~/FVC \< 0.7; and mixed disorder, %FVC \< 80 and FEV~1~/FVC \< 0.7. The annual change in FEV~1~ (%/year) was calculated as (\[value of 2011 spirometry - value of initial spirometry\]/value of initial spirometry) × 100/ time between observations (years).

Statistical analyses
--------------------

For continuous variables, data are presented as the mean and standard deviation (SD). For multiple comparisons, a 1-way analysis of variance was used along with Tukey\'s test. Correlations between 2 variables were evaluated using Pearson\'s product moment correlation coefficient. A multiple linear regression analysis was performed to determine whether plasma adiponectin levels contributed to annual changes in FEV~1~ after adjustment for all other variables included in the model. Statistical significance was inferred for 2-sided *P*-values \< 0.05. All statistical analyses were performed using JMP version 8 software (SAS Institute Inc., Cary, NC, USA).

Results
=======

The median (interquartile range) of plasma adiponectin levels was 7.1 µg/mL (5.2, 10.0) in men and 10.5 μg/mL (7.5, 15.0) in women. Table [1](#T1){ref-type="table"} shows the characteristics of the subjects according to their adiponectin level quartile. Age and high-density lipoprotein-cholesterol (HDL-c) increased in accordance with increased adiponectin level quartile in both men and women. In contrast, body mass index (BMI), alanine aminotransferase (ALT), triglycerides (TG), and FEV~1~/FVC decreased with increasing adiponectin level quartile in both men and women. BI decreased with increases in adiponectin level only in men. FVC% predicted and FEV~1~% predicted in both men and women and BI in women remained unchanged with increases in adiponectin levels.

Table [2](#T2){ref-type="table"} shows the mean plasma adiponectin levels according to the spirometric classifications (i.e., normal, restrictive, obstructive, and mixed ventilatory disorders). Plasma adiponectin levels in patients with obstructive disorders were significantly higher than those in normal subjects (Tables [2](#T2){ref-type="table"}A and B). The plasma adiponectin levels in women with obstructive disorders were higher than in those with restrictive disorders (Table [2](#T2){ref-type="table"}B).

Figure [1](#F1){ref-type="fig"} shows the relationship between plasma adiponectin levels and FEV~1~/FVC in men (Figure [1](#F1){ref-type="fig"}A) and women (Figure [1](#F1){ref-type="fig"}B). There was a significant inverse relationship between adiponectin levels and FEV~1~/FVC in both men and women. Because the degree of airflow obstruction is usually evaluated by FEV~1~, we evaluated whether adiponectin is predictive for airflow obstruction progression in a general population by assessing the relationship between plasma adiponectin levels and longitudinal changes in FEV~1~. An inverse relationship was observed in both men and women (Figure [2](#F2){ref-type="fig"}). A multiple linear regression analysis revealed that adiponectin was a significant determinant of annual changes in FEV~1~ in both men and women, and independent of other confounding factors such as age, BMI, BI, ALT, TG, and HDL-c (Table [3](#T3){ref-type="table"}). Next, the relationships between adiponectin and annual changes in FEV~1~ were assessed separately according to smoking status. As shown in Table [4](#T4){ref-type="table"}, this relation was significant in men who had never smoked and in current smokers, but not in men who were ex-smokers. In women, this relation did not reach statistical significance for any smoking status, although there was a trend that higher adiponectin levels were associated with a greater decline in FEV~1~ in women who had never smoked (*P* = 0.0594, women who never smoked, Table [4](#T4){ref-type="table"}).

Discussion
==========

In the present study, we demonstrated an inverse correlation between plasma adiponectin levels and FEV~1~/FVC in a general Japanese population (Figure [1](#F1){ref-type="fig"}). In addition, plasma adiponectin levels were inversely associated with annual changes in FEV~1~ (Figure [2](#F2){ref-type="fig"}), even after adjusting for confounding factors such as age, BMI, BI, ALT, TG, and HDL-c (Table [3](#T3){ref-type="table"}). This association was significant not only in men who were current smokers, but also in those who had never smoked (Table [4](#T4){ref-type="table"}).

Adiponectin is an adipocytokine that is derived from adipocytes. Adiponectin inhibits the expression of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha [@B25]. Low levels of adiponectin have been reported to be related to high levels of C-reactive protein, a biomarker of inflammation, in patients with obesity, type 2 diabetes, or coronary artery disease [@B25]. In addition, adiponectin alters the phenotype of macrophages from pro-inflammatory macrophages (M1) to anti-inflammatory macrophages (M2) [@B26]. Therefore, there is accumulating evidence that suggests the role of adiponectin in anti-inflammatory, anti-atherosclerotic, and cardio-protective pathways [@B25].

To date, 3 institutes have reported on pulmonary phenotypes in adiponectin-deficient mice. Summer\'s and Nakanishi\'s groups demonstrated the development of emphysematous changes in adiponectin-deficient mice [@B12],[@B13]. In null mice, alveolar macrophage activation and the secretion of matrix metalloproteinase-12, a macrophage-derived protease that promotes emphysema, were confirmed [@B13]. In addition, they observed emphysematous development in accordance with aging; further, the extra-pulmonary phenotypes were commonly observed in human COPD patients, such as weight loss, fat atrophy, and osteoporosis [@B12]. These results are in accordance with evidence that adiponectin has anti-inflammatory properties, and that the loss of adiponectin results in a reduced protective capacity against the development of emphysema. However, as many studies have shown, circulating adiponectin levels in patients with COPD were not reduced; in fact, they were increased [@B9], [@B27]-[@B29]. Even if adiponectin is anti-inflammatory and pulmonary-protective, the elevation of adiponectin levels is not enough to suppress the impairment of pulmonary function in COPD patients. In contrast, Miller et al. demonstrated that adiponectin deficiency protected mice from tobacco-induced inflammation and increased emphysema [@B14]. Thus, their new evidence showing the pro-inflammatory effects of adiponectin challenges the established theory regarding the anti-inflammatory role of adiponectin. They demonstrated that adiponectin deficiency suppressed the production of pro-inflammatory cytokines such as TNF-alpha and keratinocyte-derived chemokines in the lungs, which resulted in the protection of the lungs from cigarette smoke in adiponectin-null mice. Their study on adiponectin-deficient mice agrees with clinical evidence that shows an elevation of adiponectin in COPD patients.

Globular adiponectin is a proteolytic cleavage fragment consisting of the globular C-terminal domain of full-length adiponectin [@B30]. Proteases secreted from leukocytes are thought to cleave adiponectin to generate a globular fragment of adiponectin. In contrast to full-length adiponectin, it has been reported that globular adiponectin has the potential to induce inflammation [@B14], [@B31], [@B32]. In addition, the receptor for globular adiponectin is adiponectin receptor 1, and has been reported to be expressed in airway epithelial cells in COPD patients [@B33], [@B34]. Because the kit for adiponectin detection in the present study used 2 antibodies that recognize the collagenous domain of adiponectin, the measured adiponectin concentration demonstrated in the present study did not contain those in globular form. According to the instruction manual of another commercial enzyme-linked immunosorbent assay kit for human globular adiponectin (Alpha Diagnostic International, San Antonio TX, USA) [@B35], the mean serum level of globular adiponectin was 0.16 μg/mL (0.06-0.65 μg/mL). Although the concentrations of globular adiponectin of subjects in the present study are currently unknown, those in subjects with reduced FEV~1~ values may be elevated by the proteolytic milieu in obstructive subjects [@B1], resulting in the promotion of airway inflammation linked to airflow obstruction. Further investigations are required regarding this point.

Previously, we demonstrated that hyperhomocysteinemia and lower serum iron levels were predictive of a rapid decline in FEV~1~ in men who were continuing smokers using the Takahata Study database between 2004-2006 (Visit 1) and 2009 (Visit 2) (n = 147) [@B16], [@B19]. In 2011 (Visit 3), we re-performed the pulmonary function measurements for 873 participants in this study. Not only men who were current smokers, but also women and other subjects with smoking status were included in the analyses. During the follow-up period, many active smokers quit smoking. During Visit 1, the active smokers included 521 men (total male subjects, 1500) and 99 women (total female subjects, 1753) [@B17], [@B18]. Finally, during Visit 3, there were 50 men who were continuing smokers (total male subjects, 405) and 9 women (total female subjects, 467). Neither homocysteine nor serum iron levels were associated with changes in FEV~1~ between Visit 1 and Visit 3, suggesting that these variables predict declines only in continuing smokers (data not shown). In contrast, adiponectin predicted declines in FEV~1~ for both genders and for any smoking status.

The present study has other limitations because it was not hospital-based. Further, the lack of the information regarding chest radiography findings, the final pulmonary disease diagnosis, and current medication use, which could affect adiponectin values, may be potential limitations. In addition, there is the possibility of a sampling bias among the subjects who participated in the present study, specifically resulting from the socioeconomic status of these patients.

In conclusion, we demonstrated an inverse relationship between plasma adiponectin levels and FEV~1~/FVC in a healthy Japanese population. In addition, adiponectin levels were inversely associated with annual changes in FEV~1~, even after the adjusting for possible confounding factors. In contrast to clinical evidence regarding the cardio-protective role of adiponectin, many studies demonstrated elevation of adiponectin in clinical COPD patients, suggesting pro-inflammatory and destructive roles in the lungs. The results of the present study were in accordance with previous clinical studies regarding adiponectin levels in COPD patients. Since adiponectin levels were significantly associated with annual declines in FEV~1~, they predict declines in pulmonary function in the general population, both in smokers and in those who have never smoked.
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![**Plasma adiponectin levels were inversely correlated with forced expiratory volume in 1 s per forced vital capacity.**Graphs show the relationships between forced expiratory volume in 1 s \[FEV~1~\]/forced vital capacity \[FVC\] and plasma adiponectin levels in men (A) and women (B). Correlations were evaluated using Pearson\'s product moment correlation coefficient. A statistically significant relationship was observed in both men and women (A, *r* = -0.07, *P* = 0.01; B, *r* = -0.08, *P* = 0.001).](ijmsv11p0758g001){#F1}

![**Plasma adiponectin levels were inversely correlated with annual changes in forced expiratory volume in 1 s.**The graphs show the relationships between annual decline in forced expiratory volume in 1 s (FEV~1~) and plasma adiponectin levels in men (A) and women (B). Correlations were evaluated using Pearson\'s product moment correlation coefficient. A statistically significant relationship was observed in both men and women (A, *r* = -0.17, *P* = 0.001; B, *r* = -0.10, *P* = 0.033).](ijmsv11p0758g002){#F2}

###### 

Characteristics of the subjects according to adiponectin level quartile.

  ------------------------ ------------------ ------------------ -------------------- -------------------- ---------------
  **Men**                                                                                                  
                           **Q1 (n = 390)**   **Q2 (n = 390)**   **Q3 (n = 394)**     **Q4 (n = 398)**     ***P*-value**
  Age, years               59.2 (9.9)         61.5 (9.9)\*       62.9 (10.2)\*        67.9 (9.8)\*^\#¶^    \< 0.0001
  BMI, kg/m^2^             24.5 (2.7)         23.9 (2.9)\*       23.4 (2.8)\*         22.1 (2.9)\*^\#¶^    \< 0.0001
  BI, cigarettes × years   485.7 (487.4)      467.8 (495.3)      433.5 (529.9)        369.9 (447.9)\*      0.0158
  ALT, U/L                 30.3 (15.7)        27.6 (19.3)        24.1 (12.0)\*^\#^    21.3 (11.1)\*^\#¶^   \< 0.0001
  TG, mg/dL                151.8 (93.4)       126.4 (84.1)\*     108.3 (69.2)\*^\#^   86.3 (51.0)\*^\#¶^   \< 0.0001
  HDL-c, mg/dL             50.4 (12.0)        53.8 (14.1)\*      57.4 (14.0)\*^\#^    62.9 (14.8)\*^\#¶^   \< 0.0001
  %FVC                     96.2 (12.9)        97.4 (14.1)        98.3 (15.0)          97.1 (17.1)          0.2494
  %FEV~1~                  94.8 (15.7)        96.4 (15.8)        95.6 (17.7)          95.0 (20.2)          0.5937
  FEV~1~/FVC, %            77.7 (7.6)         77.9 (7.9)         76.4 (9.5)           76.1 (10.2)^\#^      0.0081
  **Women**                                                                                                
                           **Q1 (n = 463)**   **Q2 (n = 484)**   **Q3 (n = 476)**     **Q4 (n = 482)**     ***P*-value**
  Age, years               60.1 (10.3)        61.1 (10.3)        63.2 (10.0)\*^\#^    64.4 (10.3)\*^\#^    \< 0.0001
  BMI, kg/m^2^             24.7 (3.3)         23.8 (3.3)\*       23.4 (3.3)\*         22.1 (3.2)\*^\#¶^    \< 0.0001
  BI, cigarettes × years   22.7 (99.9)        20.4 (112.9)       9.4 (54.5)           16.7 (90.3)          0.14
  ALT, U/L                 24.8 (14.8)        21.2 (11.7)\*      20.5 (13.1)\*        19.2 (10.3)\*        \< 0.0001
  TG, mg/dL                115.7 (52.9)       105.7 (50.3)\*     93.4 (39.6)\*^\#^    79.6 (34.4)\*^\#¶^   \< 0.0001
  HDL-c, mg/dL             55.8 (12.9)        58.9 (12.6)\*      62.0 (13.7)\*^\#^    69.2 (14.5)\*^\#¶^   \< 0.0001
  %FVC                     98.3 (13.9)        100.4 (13.2)       100.5 (14.5)         100.4 (15.5)         0.0686
  %FEV~1~                  99.1 (14.9)        100.1 (14.9)       99.9 (15.3)          99.9 (16.6)          0.7634
  FEV~1~/FVC, %            81.0 (5.8)         79.9 (6.1)         79.4 (6.6)\*         79.4 (7.4)\*         0.0011
  ------------------------ ------------------ ------------------ -------------------- -------------------- ---------------

Men: Q1 \[adiponectin (μg/mL) \< 5.2\]; Q2 \[5.2 ≤ adiponectin (μg/mL) \< 7.1\]; Q3 \[7.1 ≤ adiponectin (μg/mL) \< 10.0\]; Q4 \[adiponectin (μg/mL) ≥ 10.0\] .

Women: Q1 \[adiponectin (μg/mL) \< 7.5\]; Q2 \[7.5 ≤ adiponectin (μg/mL) \< 10.5\]; Q3 \[10.5 ≤ adiponectin (μg/mL) \< 15.0\]; Q4 \[adiponectin (μg/mL) ≥ 15.0\].

\*: P \< 0.05 vs. Q1, ^\#^: P \< 0.05 vs. Q2, ^¶^: P \< 0.05 vs. Q3.

Values are expressed as the mean and standard deviation (SD). Differences among the quartiles were evaluated by a 1-way analysis of variance and Tukey\'s method.

BMI, body mass index; BI, Brinkman index; ALT, alanine aminotransferase; TG, triglycerides; HDL-c, high density lipoprotein-cholesterol; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 s.

###### 

Mean plasma adiponectin levels according to the type of spirometric disorder.

  --------------------- ------------------- ---------------------- ----------------------- ---------------- -----------
  **Men**                                                                                                   
                        Normal (n = 1161)   Restrictive (n = 96)   Obstructive (n = 184)   Mixed (n = 55)   *P*-value
  Adiponectin (μg/mL)   7.9 (4.5)           8.9 (5.3)              9.5 (5.0)\*             8.6 (3.9)        \< 0.0001
  **Women**                                                                                                 
                        Normal (n = 1525)   Restrictive (n = 96)   Obstructive (n = 80)    Mixed (n = 18)   *P*-value
  Adiponectin (μg/mL)   11.6 (5.8)          11.1 (6.1)             13.5 (6.0)\*^\#^        14.8 (7.5)       0.0025
  --------------------- ------------------- ---------------------- ----------------------- ---------------- -----------

Adiponectin concentrations were not available for 384 men and 410 women.

Values are expressed as the mean (SD). Differences between the groups were evaluated by a 1-way analysis of variance and Tukey\'s method.

\*: P \< 0.05 vs. the normal group, ^\#^: P \< 0.05 vs. the restrictive group.

###### 

Multiple linear regression analysis: correlations between variables and annual changes in FEV~1.~

                              Men      Women              
  --------------------------- -------- --------- -------- ---------
  **Explanatory variables**   **β**    ***P***   **β**    ***P***
  Age, years                  -0.108   0.057     -0.063   0.194
  BMI, kg/m^2^                0.000    0.994     -0.088   0.100
  BI, cigarettes × years      -0.023   0.685     -0.050   0.289
  ALT, U/L                    -0.045   0.432     0.010    0.845
  TG, mg/dL                   0.032    0.605     0.006    0.910
  HDL-c, mg/dL                -0.020   0.757     0.020    0.717
  Adiponectin, μg/mL          -0.166   0.006     -0.120   0.020

Dependent variable: annual change in FEV~1~ (%/year).

β, standard partial regression coefficient; BMI, body mass index; BI, Brinkman index; ALT, alanine aminotransferase; TG, triglycerides; HDL-c, high density lipoprotein-cholesterol.

###### 

Univariate linear regression analysis: correlations between annual change in FEV~1~ and plasma adiponectin levels according to gender and smoking status.

  Gender   Smoking status from 2004-2006   n     β        *P*
  -------- ------------------------------- ----- -------- --------
  Men      never                           148   -0.28    0.0006
  Men      current                         106   -0.25    0.0087
  Men      past                            151   0.002    0.9713
  Women    never                           426   -0.09    0.0594
  Women    current                         21    -0.291   0.1998
  Women    past                            9     -0.28    0.4653

Explanatory variable: plasma adiponectin level (μg/mL).

Dependent variable: annual change in FEV~1~ (%/year).

β, standard partial regression coefficient.
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